https://www.renbio.com/news_and_events/renbio-announces-new-awards-to-support-continued-development-of-its-novel-dna-based-myo-technologytm-platform-for-antiviral-applications/

The flexibility
to go further

the representation of a cell

MYO Technology is superior

Traditional protein therapeutic treatments require large doses of short acting medicine on top of the high costs of production and cold chain logistics. MYO Technology removes these hurdles with long-lasting, less-frequent, more streamlined treatment regimens without the logistical hurdles of cold chain management and long, costly, manufacturing processes.

the representation of an antibody
the representation of an antibody
the representation of an antibody
the representation of an antibody

MYO Technology is a platform

MYO Technology is a true platform technology with the flexibility to go beyond traditional treatment paradigms. By varying the DNA blueprints being delivered, MYO Technology can support virtually any encoded protein product.

Clinical Applications

Blood disorders icon
Blood disorders

Long-lasting delivery of therapeutic proteins can improve treatment of chronic blood disorders.

Inflammatory diseases icon
Inflammatory diseases

Monoclonal antibodies are a critical class of drugs for treatment of inflammatory diseases.

Viral infections
Viral infections

Viral infections can be prevented by the prophylactic use of antiviral antibodies, and their delivery with MYO Technology would provide lasting protection.